Working… Menu

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer (IMMUN-HER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03144947
Recruitment Status : Recruiting
First Posted : May 9, 2017
Last Update Posted : February 27, 2019
University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit
University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology
University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione
Clirest s.r.l.
Mipharm SpA
Arithmos srl
Temas srl
Information provided by (Responsible Party):
Gruppo Oncologico Italiano di Ricerca Clinica

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 15, 2019
Estimated Study Completion Date : November 2021